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Abstract
Background: Amblyopia (“lazy eye”) is the commonest vision deficit in children. If not fully corrected by glasses,
amblyopia is treated by patching or blurring the better-seeing eye. Compliance with patching is often poor.
Computer-based activities are increasingly topical, both as an adjunct to standard treatment and as a platform for
novel treatments. Acceptability by families has not been explored, and feasibility of a randomised controlled trial
(RCT) using computer games in terms of recruitment and treatment acceptability is uncertain.
Methods: We carried out a pilot RCT to test whether computer-based activities are acceptable and accessible to
families and to test trial methods such as recruitment and retention rates, randomisation, trial-specific data collection
tools and analysis. The trial had three arms: standard near activity advice, Eye Five, a package developed for children
with amblyopia, and an off-the-shelf handheld games console with pre-installed games. We enrolled 60 children age
3–8 years with moderate or severe amblyopia after completion of optical treatment.
Results: This trial was registered as UKCRN-ID 11074. Pre-screening of 3600 medical notes identified 189 potentially
eligible children, of whom 60 remained eligible after optical treatment, and were enrolled between April 2012 and
March 2013. One participant was randomised twice and withdrawn from the study. Of the 58 remaining, 37 were boys.
The mean (SD) age was 4.6 (1.7) years. Thirty-seven had moderate and 21 severe amblyopia. Three participants were
withdrawn at week 6, and in total, four were lost to follow-up at week 12. Most children and parents/carers found the
study procedures, i.e. occlusion treatment, usage of the allocated near activity and completion of a study diary, easy.
The prescribed cumulative dose of near activity was 84 h at 12 weeks. Reported near activity usage numbers were close
to prescribed numbers in moderate amblyopes (94 % of prescribed) but markedly less in severe amblyopes (64 %).
Reported occlusion usage at 12 weeks was 90 % of prescribed dose for moderate and 33 % for severe amblyopes.
Conclusions: Computer-based games and activities appear acceptable to families as part of their child’s amblyopia
treatment. Trial methods were appropriate and accepted by families.
Keywords: Amblyopia, Child, Clinical trial
* Correspondence: annegret.dahlmann-noor@moorfields.nhs.uk
1NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL
Institute of Ophthalmology, 162 City Road, London EC1V 2PD, UK
2Moorfields at Bedford Hospital NHS Trust, Kempston Road, Bedford MK42
9DJ, UK
Full list of author information is available at the end of the article
© 2015 Tailor et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Tailor et al. Pilot and Feasibility Studies    
DOI 10.1186/s40814-015-0018-y
Background
With a prevalence of between 2 and 5 %, amblyopia is
the commonest visual deficit in children in the UK [1, 2].
In developing countries, amblyopia is the second most
common cause of functional low vision in children [3]. It
is a developmental defect; the most common risk factors
are anisometropia (a difference in glasses prescription be-
tween the two eyes) and strabismus (misalignment of the
visual axes). The imbalance of input to the brain from the
two eyes results in a range of vision defects such as a
reduction in acuity (resolution) and abnormal binocular
function (poor stereopsis/3D vision). Unless treated early,
amblyopia is irreversible. Accidents affecting the better-
seeing eye can lead to a loss of quality of life and inde-
pendence [4].
Based on previous randomised controlled trials (RCT)
amblyopia is treated in a stepwise approach. Visually
significant refractive errors are corrected by wearing
glasses; this initial period of “refractive adaptation” or
“optical treatment” may extend to 16–18 weeks [5–7].
If residual amblyopia persists, the better-seeing eye is
patched for 2 or 6 h a day, depending on severity [8, 9].
Blurring of vision by atropine drops may be as effective
[10]. Many units in the UK offer parents the choice of
patching or atropine, but many parents favour occlusion, be-
cause treatment duration is more precise (i.e. only when the
patch is on) and because of safety concerns over perman-
ently blurring the vision in the better-seeing eye [11, 12].
Even with best treatment, not all children achieve
normal visual acuity in the amblyopic eye. Only around
25 % of those with severe amblyopia and 58 % of those
with moderate amblyopia improve to a level of 6/9
(0.18 logMAR) or better [13, 14], reflecting the need for
refinement of existing and development of new treatments.
Compliance is a significant barrier. Children attempt to re-
move the patch, and parents may feel guilty about exposing
their child to occlusion. Compliance ranges from 41–57 %
[15–17]. Compliance may be less with greater prescribed
daily dose and greater severity of amblyopia [15], pro-
longed treatment duration and lower appointment at-
tendance [17]. Better education of families may increase
compliance [16]. A broader approach based on current
knowledge [18] as well as further research to offer indi-
vidualised treatments could further improve amblyopia
treatment.
Near activities such as drawing, colouring, or playing
computer games during patching are generally considered
to improve treatment effectiveness and were included in a
previous RCT [19]. A recent RCT investigating the role of
near activities did not demonstrate an effect on visual out-
come but did not standardise near activities [20].
Computer games may be an attractive near activity to
enhance occlusion treatment: parents can choose to allow
games only during occlusion, games distract the child, and
they provide the child with a highly repetitive fine visual
task. However, some parents are concerned about allow-
ing their children daily access to computers and computer
games, potentially limiting the use of this technology in
amblyopia treatment. It is increasingly important to ad-
dress this question, as the last few years have seen the
development of novel amblyopia treatment approaches
using dichoptic image presentation on personal or tablet
computers or mobile phones as a platform for games or
movies [21–25]. Whilst these technologies have not yet
been tested in an RCT, the lay press has reported that
simple off-the-shelf games may improve visual acuity by
encouraging wearing of the occlusion patch and improving
compliance [26]. However, standard games use visual
stimuli difficult to discern for amblyopic eyes. Moor-
fields Eye Hospital has developed a package of educa-
tional and computer- and paper-based near activities
specifically for children with amblyopia, centred on a
team of cartoon space cadets, the “Moorfields’ Eye Five”
(www.eyesite.nhs.uk). The online games can be accessed
from any home or tablet computer, and targets are of big-
ger size than in standard games, so they are easier to de-
tect by amblyopic eyes. Storylines for parents/carers to
read to children are designed to engage children and to
make them interested in the characters they can colour in.
A paper-based sticker chart is used as a record of daily
successful patching.
We aimed to determine whether computer-based near
activities, either off-the-shelf or custom-designed for am-
blyopia, improve adherence to occlusion treatment. How-
ever, as many parameters surrounding study design and
feasibility, particularly recruitment and treatment accept-
ability to families, were unknown, we carried out a pilot
trial for a later phase III randomised controlled trial. The
aims of this pilot trial are to test recruitment and retention
rates, acceptability and accessibility of computer games to
children and parents/carers, randomisation, trial-specific
data collection tools and analysis.
Methods
This RCT was approved by the National Research Ethics
Committee London—London Bridge, and registered on
the UKCRN portfolio database as UKCRN-ID 11074.
Study design
We conducted an observer-masked, parallel-group RCT,
randomising a total of 60 children age 3–8 years with
unilateral amblyopia to either the Moorfields’ Eye Five
Package or a game on a handheld Nintendo 3DS console
or standard occlusion treatment, using a 1:1:1 allocation
ratio. The sample size of 20 participants per arm is com-
monly used in pilot trials [27].
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Study setting
We identified children between April 2012 and March
2013 at clinics at Moorfields Eye Hospital, Moorfields at
Bedford Hospital, the South Essex Partnership Foundation
Trust Orthoptic Community Eye Clinics in Bedford and
the Homerton Hospital. We pre-screened the medical
notes of all newly referred children to identify those re-
ferred for reduced vision and/or strabismus.
Inclusion criteria
We included children age 3–8 years with newly diagnosed
anisometropic, strabismic or combined mechanism ambly-
opia. Children had completed a period of optical treatment,
and a clinical indication to start additional treatment
had been made. Parents/carers had been given a choice
between occlusion or pharmacological blurring and had
decided that they would prefer occlusion treatment.
Children had an interocular difference in best corrected
visual acuity (BCVA) at least 0.20 logMAR and no previ-
ous ophthalmic treatment other than glasses. All children
had access to a desktop, laptop or tablet computer at
home, with variable screen size.
Recruitment
As part of their clinical management, all children under-
went comprehensive orthoptic and ophthalmic assessment
including cycloplegic refraction and fundoscopy; glasses
were prescribed as appropriate. BCVA was monitored at
intervals of 6–10 weeks. We defined the end of “optical
treatment only” as BCVA not improving on two consecu-
tive visits despite reportedly good compliance. If children
were eligible at the end of optical treatment, we gave
families verbal and written information about the trial.
Following at least 2 weeks to consider participation, a
research orthoptist with training in Good Clinical Practice
explained the study procedures, addressed any questions
and obtained written parental/carer consent at the sub-
sequent clinic visit; children gave verbal assent; written
assent was optional.
Baseline assessment
The study orthoptist carried out a baseline assessment
of BCVA and stereopsis on an age-appropriate test.
BCVA was measured using Thompson V2000 software
which displays HOTVX letters or Kay pictures at 3 m or
handheld Keeler or Kays crowded logMAR charts. Visual
acuity was recorded in logMAR. Stereopsis was measured
using Frisby, TNO or the Titmus fly test and recorded in
seconds of arc. Whilst tests varied between participants,
each participant had the same test for visual acuity and
stereoacuity at all timepoints.
Randomisation/allocation
A randomisation schedule was prepared based on per-
muted blocks of varying sizes by a data manager within
the R & D department. When a child had been recruited
to the trial, the orthoptist telephoned the data manager
to find out what the next treatment on the schedule was.
It was not possible to mask families to the treatment,
but research staff was masked where possible, e.g. data
were collected by staff who did not know which treatment
participants were receiving, and the participants were
asked not to disclose their treatment to the examining
health professionals.
Interventions
As experimental interventions, we used (1) a Super Mario
World game on a handheld Nintendo 3DS console and
(2) the Moorfields’ Eye Five Package, a web-based
programme of educational and near activities for chil-
dren with amblyopia. The package combines a cartoon
story book, paper-based activities such as colouring pages
and puzzles, and internet-based computer games (http://
www.eyesite.nhs.uk/). Children who were allocated the
Super Mario game received a Nintendo console with the
game; those in the Eye Five group were given a paper
activity and sticker book and were asked to access the
online games via a computer at home. The comparator
was standard verbal and written instructions on near
activities such as colouring, reading and writing.
The study orthoptist gave participants and parents/carers
information about the use of the allocated near activity
which was prescribed for 1 h whilst wearing the occlusion
patch. Children were asked not to use any other con-
soles during patching. Children with moderate amblyopia
(BCVA in the amblyopic eye better than 0.6 logMAR)
were prescribed 2 h of occlusion per day; participants
with severe amblyopia (BCVA in the amblyopic eye 0.6
logMAR or worse), 6 h.
Post-randomisation assessments
We asked parents to complete a diary to monitor adher-
ence and ease of use of near activities and patching, and
reviewed the diaries at 6 and 12 weeks after randomisa-
tion. We asked children and parents/carers about any ad-
verse events and monitored BCVA in the fellow eye to
detect a reversal of amblyopia. At 12 weeks, we asked chil-
dren and parents/carers four questions about the ease of
occlusion, use of the near activity, use of parental diaries
and the effect of occlusion on the participant’s self-esteem,
using a five-point Likert scale. These questions aimed to
explore acceptability of the interventions and the study
design to children and families.
Orthoptists masked to the allocated treatment carried
out assessments of BCVA and stereoacuity at 6 and 12
weeks. All data were collected on paper-based case report
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forms completed at each treatment visit and parental diar-
ies completed daily.
Outcome measures
Primary outcome measures related to study methodology
and feasibility [28]: recruitment and retention rates and
acceptability of the experimental interventions. Secondary
outcomes included adherence to experimental and stand-
ard treatments, BCVA in the amblyopic eye, stereopsis
and adverse events. These measures were to be used to es-
timate the treatment effect size for a sample size calcula-
tion for a subsequent phase III RCT.
Sample size and statistical methods
The sample size of 20 per treatment arm is commonly
used in pilot trials [27].
STATA version 12 was used to perform data analysis.
Baseline characteristics were summarised by treatment
group to assess the adequacy of the randomisation. Num-
bers and proportions were used for categorical variables,
means and standard deviations (SD), or medians and
interquartile ranges (IQR) were used for continuous vari-
ables depending on whether the data appeared to be
normally distributed. For each participant, the number
of hours of occlusion and of near activity use was calcu-
lated by adding up the figures recorded in the parent/carer
diaries. For number of hours of occlusion and near activ-
ities (adherence measures) and for BCVA and stereopsis
(visual outcomes), we calculated the median and IQR.
Results
Primary outcomes: recruitment and retention rates and
acceptability of study methodology and interventions
Recruitment
We pre-screened the medical notes of 3600 children, iden-
tifying 189 potentially eligible patients referred for reduced
vision and/or strabismus (Fig. 1). Following screening and
discussion of the study with eligible families, we enrolled
60 children over a period of 12 months (April 2012–March
2013). All participants were recruited on the day when the
decision to start occlusion treatment was made.
One patient was enrolled twice, by different study orthop-
tists and was allocated to different treatment arms. A review
of enrolment, randomization and clearer identification of
trial patients prevented further double-enrolments. The par-
ticipant was excluded from follow-up, resulting in a loss of
Fig. 1 Consort flowchart of recruitment, allocation of intervention and 12-week analysis
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two recruitment numbers, as the family may have chosen
not to reveal the first allocation in order to receive a differ-
ent treatment.
The period of optical treatment caused a slow start to
recruitment into the trial; in the first 5 months of the
trial, an average of 1.2 (SD 1.1) children were recruited
per month; in the remaining trial period, this rose to a
mean of 7 (SD 2.6) per month.
Demographical and clinical characteristics of study
population
Of the 58 remaining participants, 37 were boys and 21
girls (Table 1). The mean (SD) age was 4.6 (1.7) years.
Thirty-seven had moderate and 21 severe amblyopia.
Median (IQR) BCVA in the amblyopic eye at baseline was
0.5 (0.34–0.7) logMAR. 24 (41 %) children had anisome-
tropic, 16 (28 %) strabismic and 16 (28 %) combined
mechanism amblyopia. In 2 (3 %) cases the diagnosis
was not clear.
Randomisation and allocation of interventions
Central randomisation was effective; there were no delays
in allocating interventions.
Retention/dropout
One child was enrolled and randomised twice, to differ-
ent arms, and subsequently withdrawn from the study
(Fig. 1). Four participants were lost to follow-up at week
12: three did not attend without giving reasons, and one
sustained an unrelated corneal abrasion and was transferred
to a different clinic. Three participants were withdrawn
at W6: one because their unaided vision was normal on
retesting and no amblyogenic risk factors were present,
one withdrew without giving reasons, and one discon-
tinued the intervention (Eye Five) and started using stand-
ard treatment, as the family felt computer games to be
too intrusive to family life. Minor protocol deviations
concerned children using the Eye Five website on tablet
computers rather than desktop PCs. This may influence
the apparent size of objects but may be compensated
for by a reduced viewing distance if tablets are held
closer to the eye.
Accessibility and acceptability of interventions and study
procedures
Fifty-one of 58 families (88 %) completed the diaries. In
all groups, most children and parents/carers found com-
pletion of the diary and usage of the allocated near activ-
ity moderately to very easy. Those diaries which were
completed were completed in full. No comments or ad-
verse events were noted. Families also reported occlusion
treatment from moderately to very easy. The effect of
patching on the child’s self-esteem was reported as be-
tween slight and moderate. The results were similar
between treatment groups.
Secondary outcomes
Adherence to prescribed near activity
The prescribed cumulative dose of near activity was 42 h
at 6 weeks and 84 at 12. Reported usage numbers were
close to prescribed numbers in moderate amblyopes
(94 % of prescribed) but markedly less in severe amblyopes
(64 %). Figures were similar across treatment groups.
Table 2 summarises compliance data.
Adherence to occlusion
The prescribed numbers of hours of occlusion at 6
weeks were 84 for moderate and 252 for severe ambly-
opia and at 12 weeks, 168 and 504 h, respectively. Despite
the difference in prescribed hours, effective hours reported
in the diaries were similar in children with moderate and
severe amblyopia. At 12 weeks, children with moderate
amblyopia had patched 90 % of the prescribed time, but
Table 1 Participant characteristics
Standard (n = 20) Eye five (n = 19) Nintendo (n = 19)
Gender, n (col %) 13(65) 12(63) 12(63)
Males 7(35) 7(37) 7(37)
Females
Age (years), median (IQR) 5.1(3.5–6) 5.1(3.5–6.1) 4.3(4–5.4)
Type of amblyopia n (col %) 5(25) 11(57.9) 8(42.1)
Anisometropic 6(30) 5(26.3) 5(26.3)
Strabismus 8(40) 2(10.5) 6(31.6)
Mixed 1(5) 1(5.3)
Unknown
Severity of Amblyopia 11(55) 13(68.4) 13(72.2)
Moderate 9(45) 6(11.6) 6(27.8)
Severe
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those with severe amblyopia had only received 33 % of the
prescribed dose.
Visual outcomes
Of 58 participants, data on BCVA were available in 53 at
the 6- and 51 at the 12-week timepoint (91 and 88 %),
and stereopsis data were available in 52 patients at 6
weeks and 50 at 12 weeks (90 and 86 %). At 12 weeks
data were available for 18 in the standard group, 15 in
the Eye Five group and 18 in the Nintendo Group.
BCVA improved at both 6 and 12 weeks in all three
groups. At 12 weeks, median BCVA in children with se-
vere amblyopia in the standard advice group improved
by 0.27, in the Eye Five group by 0.26 logMar and in the
Nintendo group by 0.26 logMar. In children with moder-
ate amblyopia, median BCVA improved by 0.08, 0.2 and
0.26 logMar, respectively. Table 3 summarises visual out-
come data.
Adverse events
The only reported adverse event was intrusiveness of
computer games on family life in one participant.
Discussion
This pilot trial addresses the question whether a full phase
III trial of computer-based near activities would be feas-
ible, i.e. whether families would accept computer-based
games and activities as part of their child’s amblyopia
treatment and whether the study methods were accept-
able. The pilot demonstrated a number of methodological
weaknesses, but improved methods, recruitment and ac-
ceptability data show that a future RCT would be feasible.
The challenges we encountered may inform future trials
in this field. Recruitment was initially slow due to pre-
enrolment optical treatment. In addition, 17 % of children
in our cohort improved on optical treatment to a point
where they no longer met the eligibility criteria for this
trial. This figure is consistent with other series (10 to
27 %) [29, 6, 7]. Seven of 58 children (12 %) did not
complete the study; these figures will inform sample size
calculations for future trials. The interventions were
acceptable to families; only one participant withdrew
from the study due to computer games being disruptive to
family life. This is greatly encouraging for the planning
of future trials, such as those involving computer-based
dichoptic image presentation.
Of note, some children accessed web-based games via
tablet computers rather than desktops or laptops. The
Eye Five activities were developed to encourage use by
children with amblyopia by presenting larger targets than
off-the-shelf games. This trial shows that children enjoyed
playing these games, and a wider range of games and
activities is now in preparation. As children can com-
pensate for smaller object size on tablet computer screens
by holding the screen closer to their eyes, future stud-
ies should allow use of any computer as part of the
protocol.
Diaries to measure compliance were well accepted by
families; 88 % were completed. Ideally, compliance should
be measured objectively by occlusion dose monitors
(ODM) [6, 30], as the effective occlusion dose may be
less than 50 % of the prescribed dose [17]. When our
trial was set up, ODMs were not commercially avail-
able, and developing ODMs exceeded the study budget.
We therefore opted for parental/carer diaries. Pragmatic
amblyopia treatment studies have reported outcomes
based on prescribed occlusion dose [13, 14, 31]. The re-
ported usage of near activities and occlusion overall was
as expected from previous reports, confirming the validity
of this approach.
Table 2 Hours spent on prescribed near activity and reported hours of occlusion treatment at the 6- and 12-week review
Compliance median (IQR) Standard (N = 20) Eye 5 (N = 19) Nintendo (N = 19) Total (N = 58)
Cumulative hours of near activity
Moderate amblyopia 0–6 wks 42 (21–48), n = 11 39 (11–43), n = 12 42 (32–54), n = 12 42 (21–48), n = 35
Severe amblyopia 0–6 wks 23 (8–39), n = 8 29 (9–42), n = 5 12 (8–18), n = 5 20 (8–40), n = 18
Moderate amblyopia 0–12 wks 77 (63–84), n = 10 76 (30–84), n = 10 79 (68–99), n = 12 79 (61–84), n = 32
Severe amblyopia 0–12 wks 49 (24–81), n = 8 70 (34–82), n = 4 24 (17–118), n = 5 54 (17–82), n = 17
Cumulative hours of occlusion
Moderate amblyopia 0–6 wks 84 (60–88), n = 11 66 (36–82), n = 12 74 (46–82), n = 12 72 (51–84), n = 35
Severe amblyopia 0–6 wks 74 (64–145), n = 8 84 (61–94), n = 5 96 (86–126), n = 5 85 (64–98), n = 18
Moderate amblyopia 0–12 wks 158 (126–180), n = 10 139 (97–164), n = 10 156 (93–168), n = 12 153 (108–168), n = 32
Severe amblyopia 0–12 wks 190 (141–292), n = 8 146 (125–159), n = 4 351 (160–432), n = 5 168 (142–351), n = 17
N = total number of patients in the study arm, n = number of patients in the group with valid data (only shown when there is invalid or missing data); The
prescribed numbers of hours of near activity use were 42 at 6 and 84 at 12 weeks. Children with moderate amblyopia used the prescribed near activity markedly
more than children with severe amblyopia. The prescribed numbers of hours of occlusion at 6 weeks were 84 for moderate and 252 for severe amblyopia and at
12 weeks 168 and 504 h, respectively. Despite the difference in prescribed hours, effective hours reported in the diaries were similar in children with moderate
and severe amblyopia
IQR interquartile range
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Table 3 BCVA and stereoacuity at 6 and 12 weeks
Visual outcomes Standard (n = 20) Median (IQR) Eye 5 (n = 19) Median (IQR) Nintendo(n = 19) Median (IQR)
Baseline BCV Severe Moderate None Severe Moderate None Severe Moderate None
Amblyopic or non-amblyopic eyes n = 9 n = 11 n = 20 n = 5 n = 13 n = 19 n = 6 n = 13 n = 18
0.8 (0.8–1) 0.36 (0.32–0.5) 0.1 (0.01–0.12) 0.76 (0.7–0.78) 0.35 (0.3–0.5) 0.1 (0.05–0.14) 0.8 (0.7–0.9) 0.4 (0.32–0.46) 0.1 (0.02–0.12)
6 weeks VA Severe Moderate None Severe Moderate None Severe Moderate None
Amblyopic or non-amblyopic eyes n = 8 n = 11 n = 19 n = 5 n = 12 n = 17 n = 5 n = 12 n = 17
0.6 (0.59–0.89) 0.22 (0.06–0.4) 0.1 (0–0.15) 0.62 (0.58–0.75) 0.25 (0.19–0.31) 0.06 (0.05–0.12) 0.5 (0.5–0.7) 0.25 (0.2–0.38) 0.1 (0–0.1)
12 weeks VA Severe Moderate None Severe Moderate None Severe Moderate None
Amblyopic or non-amblyopic eyes n = 8 n = 10 n = 18 n = 4 n = 11 n = 15 n = 6 n = 12 n = 18
0.53 (0.47–0.73) 0.28 (0.12–0.4) 0.1 (0–0.14) 0.5 (0.46–0.59) 0.15 (0.1–0.2) 0.06 (0.02–0.1) 0.54 (0.5–0.58) 0.14 (0.1–0.31) 0.01 (0–0.1)
Stereopsis
Baseline 0 (0–155) 110 (0–170) 110 (0–480)
6 weeks 0 (0–170), N = 19 85 (0–170), N = 16 110 (70–170), N = 17
12 weeks 0 (0–100), N = 18 85 (0–100), N = 14 85 (0–110), N = 18
N = total number of patients in the study arm, n = number of patients in the group with valid data (only shown when there is invalid or missing data); At 12 weeks, median BCVA in children with severe amblyopia in
the standard advice group improved by 0.27, in the Eye Five group by 0.26 logMar and in the Nintendo group by 0.26 logMar. In children with moderate amblyopia, median BCVA improved by 0.08, 0.2 and 0.26













This pilot study also provides preliminary data on
compliance with treatment and visual outcomes. Com-
pliance with occlusion as reported by diaries appeared
similar between groups. Children with moderate ambly-
opia received 90 % of the prescribed patching dose but
those with severe amblyopia only 33 %. This means that
those with severe amblyopia effectively patched for the
same amount of time per day as moderate amblyopes,
i.e. 2 h. Our figures are more extreme than those re-
ported by other studies which report 41–57 % [15–17].
The only other RCT that specifically explored the use
of near activities prescribed 2 h of patching and near
activity to children with moderate and severe amblyopia
and observed that children received 95 % of the prescribed
regime [20]. The children in our study effectively received
the same dose. Interestingly, visual outcomes are also
similar; as this RCT reported mean improvement of
BCVA of 2.5 at 8 and 2.9 lines at 17 weeks [20]. Another
secondary aim was to estimate treatment effect size on
visual outcomes for future sample size calculations. The
“gold standard” method to measure visual acuity in adults
is the ETDRS letter chart, which is based on linear
presentation and letter-by-letter logarithmic scoring. The
equivalent “gold standard” for children is a simplified
crowded logMAR test, such as the Keeler crowded
logMAR chart (originally described as “Glasgow Acuity
Cards” [32, 33]. This test has a 95 % confidence interval
for test-retest variability of 0.1 logMAR [33], which we
selected as minimum clinically important difference which
we wished to detect. Younger children may not co-operate
letter recognition on the Keeler crowded logMAR test;
hence, the crowded Kay Pictures test is often used in
children age 2 to 4 years, though data on test reliability
in children are sparse [34–36]. When we started this
study, we considered that any chart giving a logMAR
visual acuity measurement would be acceptable for this
pragmatic study. However, due to the lack of validation
of tests for younger children, a definitive clinical trial
would be more rigorous if the “gold standard” acuity test
was carried out on all children and at all timepoints. This
would mean that children who cannot co-operate with
this test cannot enter the study.
The use of different test charts is a significant limita-
tion of the present, pragmatic pilot trial and may impact
the sample size calculation for future trials, but our find-
ings with regards to improvements in visual acuity are
similar to those reported by previous studies. Overall,
BCVA improved by 0.26 to 0.27 logMAR in severe and
0.08 to 0.26 logMAR in moderate amblyopes. This is simi-
lar to previous figures of 0.12–0.35 logMAR [29, 6, 13, 14].
Considering the data on controls subjects in our study
only, the mean change in BCVA was 0.21 (SD 0.13). For
a study with two arms, a sample size of 32 in each group
will have 85 % power to detect a difference in means of
0.100 (the difference between a Group 1 mean, μ1, of
0.210 and a Group 2 mean, μ2, of 0.110) assuming that
the common standard deviation is 0.130 using a two
group t test with a 0.050 two-sided significance level.
Allowing for possible loss to follow-up of 5 %, a total
sample size of 68 children would be required.
Since we conducted this pilot trial, binocular treatment
approaches have become available for adults and children
with amblyopia [21–25]. We therefore decided not to
proceed to a full phase III trial of computer games to
enhance occlusion but have used the feasibility data from
this pilot to design a trial of a binocular treatment.
Conclusions
Computer-based games and activities appear acceptable
to families as part of their child’s amblyopia treatment.
Trial methods were appropriate and accepted by families.
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